These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 28677496)

  • 1. Metabolic Syndrome, Dyslipidemia and Regulation of Lipoprotein Metabolism.
    Iqbal J; Al Qarni A; Hawwari A; Alghanem AF; Ahmed G
    Curr Diabetes Rev; 2018; 14(5):427-433. PubMed ID: 28677496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
    Ascaso J; Gonzalez Santos P; Hernandez Mijares A; Mangas Rojas A; Masana L; Millan J; Pallardo LF; Pedro-Botet J; Perez Jimenez F; Pintó X; Plaza I; Rubiés J; Zúñiga M
    Am J Cardiovasc Drugs; 2007; 7(1):39-58. PubMed ID: 17355165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.
    Adiels M; Olofsson SO; Taskinen MR; Borén J
    Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1225-36. PubMed ID: 18565848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catabolism of lipoproteins and metabolic syndrome.
    Therond P
    Curr Opin Clin Nutr Metab Care; 2009 Jul; 12(4):366-71. PubMed ID: 19474714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights into the pathophysiology of dyslipidemia in type 2 diabetes.
    Taskinen MR; Borén J
    Atherosclerosis; 2015 Apr; 239(2):483-95. PubMed ID: 25706066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of dyslipidemia to reduce cardiovascular risk in patients with multiple risk factors.
    Ballantyne CM
    Clin Cornerstone; 2007; 8 Suppl 6():S6-13. PubMed ID: 17948362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives.
    Chapman MJ
    Atherosclerosis; 2003 Nov; 171(1):1-13. PubMed ID: 14642400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of dyslipidemia in the metabolic syndrome.
    Tan KC
    Cardiovasc Hematol Disord Drug Targets; 2007 Jun; 7(2):99-108. PubMed ID: 17584044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-density Lipoprotein (HDL) Dysfunction and the Future of HDL.
    Ertek S
    Curr Vasc Pharmacol; 2018; 16(5):490-498. PubMed ID: 29149817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atherogenic dyslipidemia in the cardiometabolic syndrome.
    Govindarajan G; Chowdhury N; Flaker G
    J Cardiometab Syndr; 2006; 1(2):153-5. PubMed ID: 17679818
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol.
    Xiao C; Dash S; Morgantini C; Hegele RA; Lewis GF
    Diabetes; 2016 Jul; 65(7):1767-78. PubMed ID: 27329952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of ApoCIII to Diabetic Dyslipidemia and Treatment With Volanesorsen.
    Zhang J; Rocha NA; McCullough PA
    Rev Cardiovasc Med; 2018 Mar; 19(1):13-19. PubMed ID: 31032598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.
    Keating GM; Croom KF
    Drugs; 2007; 67(1):121-53. PubMed ID: 17209672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid therapy for cardiovascular disease with insulin resistance, diabetes, or the metabolic syndrome.
    Robins SJ
    Curr Cardiol Rep; 2005 Nov; 7(6):457-64. PubMed ID: 16256016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting dyslipidemia in the metabolic syndrome: an update.
    Paraskevas KI; Karatzas G; Pantopoulou A; Iliopoulos DG; Perrea D
    Curr Vasc Pharmacol; 2010 Jul; 8(4):450-63. PubMed ID: 19485929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of dyslipidemia in patients with type 2 diabetes.
    Vijayaraghavan K
    Lipids Health Dis; 2010 Dec; 9():144. PubMed ID: 21172030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
    Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
    Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
    Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
    BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.